Explore the words cloud of the Fertissimo project. It provides you a very rough idea of what is the project "Fertissimo" about.
The following table provides information about the project.
CARMEL DIAGNOSTICS LTD
|Coordinator Country||Israel [IL]|
|Total cost||2˙751˙973 €|
|EC max contribution||2˙711˙973 € (99%)|
1. H2020-EU.3.1.3. (Treating and managing disease)
|Duration (year-month-day)||from 2017-05-01 to 2020-04-30|
Take a look of project's partnership.
|1||CARMEL DIAGNOSTICS LTD||IL (QIRYAT TIVON)||coordinator||1˙446˙486.00|
|2||ARAN RESEARCH DEVELOPMENT & PROTOTYPES LTD||IL (CAESAEA)||participant||1˙265˙487.00|
Low rates of pregnancy in IVF procedure is due to being unable to identify viable embryos for transfer. As a result, multiple embryo transfer (MET) is practiced to increase the chances of pregnancy. This is a costly procedure with riskier outcomes, which on average only equates to a 1 out of 4 rate of pregnancy success. In order to minimise the cost and risk outcomes with MET, there are increasing trends have been adopted to accommodate single embryo transfer (SET). SET however, requires more efficient embryo selection tools than current legacy morphology methods.
Fertissimo utilises a novel biomarker of oxidative stress (OS) qualities that will enable the physician’s selection of viable embryos in a rapid, non-invasive, and accurate manner. Fertissimo will provide a quantitative assessment of an embryo’s reproductive potential based on the oxidative profile of its incubated culture media. It will increase IVF pregnancy outcomes by an unprecedented 25% and beyond.
The Phase 2 project’s ultimate aim is to lay the foundation for dependable IVF pregnancies of the future. Fertissimo will set the gold standard for IVF procedure in all relevant IVF facilities, located in hospitals, medical centres, centres of IVF excellence, and clinics. Carmel Diagnostics will conduct a series of clinical validation studies, both retrospective and prospective, in order to qualify the novel OS biomarker to effectively predict embryo viability
Carmel Diagnostics (established in 2009) joins forces with Aran R&D, a leading engineering and product development company, forming a solid basis with all necessary knowledge capabilities, infrastructure and finances to support the innovation project. This would allow Carmel, and Aran, to develop, test, certify, and create the production line required for Fertissimo’s mass production.
The industrially produced Fertissimo can then be qualified in a conclusive clinical trial with Global IVF Leader IVI Valencia to the benefit of soon-to-be mothers
|Original Investor Relations Kit Dossier||Websites, patent fillings, videos etc.||2019-03-20 11:46:21|
|Project website||Websites, patent fillings, videos etc.||2019-03-20 11:46:21|
Take a look to the deliverables list in detail: detailed list of Fertissimo deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FERTISSIMO" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "FERTISSIMO" are provided by the European Opendata Portal: CORDIS opendata.
PanCareFollowUp: Novel, patient-centred survivorship care to improve care quality, effectiveness, cost-effectiveness and accessibility for survivors and caregiversRead More
ENDOSCAPE, a clinically applicable non-viral gene delivery technologyRead More
CeLac and European consortium for a personalized medicine approach to Gastric CancerRead More